APO RESEARCH · REPORT
Dermatology OTC Medications
Dermatology drug is used in the management and treatment of diseases related to skin. Acne, psoriasis, and dermatitis are some common skin diseases. Over-the-counter (OTC) drugs are medicines sold directly to a consumer without a prescription from a healthcare professional, as opposed to prescription drugs, which may be sold only to consumers possessing a valid prescription.
Product & engineering
Understand the product.
Dermatology drug is used in the management and treatment of diseases related to skin. Acne, psoriasis, and dermatitis are some common skin diseases. Over-the-counter (OTC) drugs are medicines sold directly to a consumer without a prescription from a healthcare professional, as opposed to prescription drugs, which may be sold only to consumers possessing a valid prescription.
Selected research
Industry Research
Dermatology OTC Medications Industry Research Report 2026
Market perspective
Dermatology drug is used in the management and treatment of diseases related to skin. Acne, psoriasis, and dermatitis are some common skin diseases. Over-the-counter (OTC) drugs are medicines sold directly to a consumer without a prescription from a healthcare professional, as opposed to prescription drugs, which may be sold only to consumers possessing a valid prescription.
Market competition is intense. Bayer, GSK, Teva, Johnson & Johnson, Novartis, Mylan, etc. are the leaders of the industry, and they hold key technologies and patents, with high-end customers. Top 5 manufacturers accounted for 25.08% market share in 2019.
Report Scope
Read the full market overview
This report quantifies the global Dermatology OTC Medications market in terms of revenue (US$ million) and, where applicable, sales volume (M Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/M Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Dermatology OTC Medications Market by Company
Bayer
GSK
Teva
Johnson & Johnson
Novartis
Mylan
Sun Pharmaceutical
Aurobindo
Galderma
CR SANJIU
Dr. Reddy's
Lupin
Bausch Health
Cipla
Qilu Pharmaceutical
Almirall
Lingrui
Dermatology OTC Medications Segment by Type
External Use
Oral
Dermatology OTC Medications Segment by Application
Hospital
Drug Store
Other
Dermatology OTC Medications Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Dermatology OTC Medications market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Dermatology OTC Medications and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Dermatology OTC Medications.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Dermatology OTC Medications manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Dermatology OTC Medications by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Dermatology OTC Medications in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- External Use
- Oral
Applications
- Hospital
- Drug Store
- Other
Companies covered
- Bayer
- GSK
- Teva
- Johnson & Johnson
- Novartis
- Mylan
- Sun Pharmaceutical
- Aurobindo
- Galderma
- CR SANJIU
- Dr. Reddy's
- Lupin
- Bausch Health
- Cipla
- Qilu Pharmaceutical
- Almirall
- Lingrui
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Dermatology OTC Medications Market Size (2021-2032)
- 2.2.2 Global Dermatology OTC Medications Sales (2021-2032)
- 2.2.3 Global Dermatology OTC Medications Market Average Price (2021-2032)
- 2.3 Dermatology OTC Medications by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 External Use
- 2.3.3 Oral
- 2.4 Dermatology OTC Medications by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Hospital
- 2.4.3 Drug Store
- 2.4.4 Other
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Dermatology OTC Medications Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Dermatology OTC Medications Sales (M Units) of Manufacturers (2021-2026)
- 3.3 Global Dermatology OTC Medications Revenue of Manufacturers (2021-2026)
- 3.4 Global Dermatology OTC Medications Average Price by Manufacturers (2021-2026)
- 3.5 Global Dermatology OTC Medications Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Dermatology OTC Medications, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Dermatology OTC Medications, Product Type & Application
- 3.8 Global Manufacturers of Dermatology OTC Medications, Established Date
- 3.9 Global Dermatology OTC Medications Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Bayer
- 4.1.1 Bayer Company Information
- 4.1.2 Bayer Business Overview
- 4.1.3 Bayer Dermatology OTC Medications Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Bayer Dermatology OTC Medications Product Portfolio
- 4.1.5 Bayer Recent Developments
- 4.2 GSK
- 4.2.1 GSK Company Information
- 4.2.2 GSK Business Overview
- 4.2.3 GSK Dermatology OTC Medications Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 GSK Dermatology OTC Medications Product Portfolio
- 4.2.5 GSK Recent Developments
- 4.3 Teva
- 4.3.1 Teva Company Information
- 4.3.2 Teva Business Overview
- 4.3.3 Teva Dermatology OTC Medications Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Teva Dermatology OTC Medications Product Portfolio
- 4.3.5 Teva Recent Developments
- 4.4 Johnson & Johnson
- 4.4.1 Johnson & Johnson Company Information
- 4.4.2 Johnson & Johnson Business Overview
- 4.4.3 Johnson & Johnson Dermatology OTC Medications Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Johnson & Johnson Dermatology OTC Medications Product Portfolio
- 4.4.5 Johnson & Johnson Recent Developments
- 4.5 Novartis
- 4.5.1 Novartis Company Information
- 4.5.2 Novartis Business Overview
- 4.5.3 Novartis Dermatology OTC Medications Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Novartis Dermatology OTC Medications Product Portfolio
- 4.5.5 Novartis Recent Developments
- 4.6 Mylan
- 4.6.1 Mylan Company Information
- 4.6.2 Mylan Business Overview
- 4.6.3 Mylan Dermatology OTC Medications Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Mylan Dermatology OTC Medications Product Portfolio
- 4.6.5 Mylan Recent Developments
- 4.7 Sun Pharmaceutical
- 4.7.1 Sun Pharmaceutical Company Information
- 4.7.2 Sun Pharmaceutical Business Overview
- 4.7.3 Sun Pharmaceutical Dermatology OTC Medications Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Sun Pharmaceutical Dermatology OTC Medications Product Portfolio
- 4.7.5 Sun Pharmaceutical Recent Developments
- 4.8 Aurobindo
- 4.8.1 Aurobindo Company Information
- 4.8.2 Aurobindo Business Overview
- 4.8.3 Aurobindo Dermatology OTC Medications Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Aurobindo Dermatology OTC Medications Product Portfolio
- 4.8.5 Aurobindo Recent Developments
- 4.9 Galderma
- 4.9.1 Galderma Company Information
- 4.9.2 Galderma Business Overview
- 4.9.3 Galderma Dermatology OTC Medications Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Galderma Dermatology OTC Medications Product Portfolio
- 4.9.5 Galderma Recent Developments
- 4.10 CR SANJIU
- 4.10.1 CR SANJIU Company Information
- 4.10.2 CR SANJIU Business Overview
- 4.10.3 CR SANJIU Dermatology OTC Medications Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 CR SANJIU Dermatology OTC Medications Product Portfolio
- 4.10.5 CR SANJIU Recent Developments
- 4.11 Dr. Reddy's
- 4.11.1 Dr. Reddy's Company Information
- 4.11.2 Dr. Reddy's Business Overview
- 4.11.3 Dr. Reddy's Dermatology OTC Medications Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 Dr. Reddy's Dermatology OTC Medications Product Portfolio
- 4.11.5 Dr. Reddy's Recent Developments
- 4.12 Lupin
- 4.12.1 Lupin Company Information
- 4.12.2 Lupin Business Overview
- 4.12.3 Lupin Dermatology OTC Medications Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 Lupin Dermatology OTC Medications Product Portfolio
- 4.12.5 Lupin Recent Developments
- 4.13 Bausch Health
- 4.13.1 Bausch Health Company Information
- 4.13.2 Bausch Health Business Overview
- 4.13.3 Bausch Health Dermatology OTC Medications Sales, Revenue and Gross Margin (2021-2026)
- 4.13.4 Bausch Health Dermatology OTC Medications Product Portfolio
- 4.13.5 Bausch Health Recent Developments
- 4.14 Cipla
- 4.14.1 Cipla Company Information
- 4.14.2 Cipla Business Overview
- 4.14.3 Cipla Dermatology OTC Medications Sales, Revenue and Gross Margin (2021-2026)
- 4.14.4 Cipla Dermatology OTC Medications Product Portfolio
- 4.14.5 Cipla Recent Developments
- 4.15 Qilu Pharmaceutical
- 4.15.1 Qilu Pharmaceutical Company Information
- 4.15.2 Qilu Pharmaceutical Business Overview
- 4.15.3 Qilu Pharmaceutical Dermatology OTC Medications Sales, Revenue and Gross Margin (2021-2026)
- 4.15.4 Qilu Pharmaceutical Dermatology OTC Medications Product Portfolio
- 4.15.5 Qilu Pharmaceutical Recent Developments
- 4.16 Almirall
- 4.16.1 Almirall Company Information
- 4.16.2 Almirall Business Overview
- 4.16.3 Almirall Dermatology OTC Medications Sales, Revenue and Gross Margin (2021-2026)
- 4.16.4 Almirall Dermatology OTC Medications Product Portfolio
- 4.16.5 Almirall Recent Developments
- 4.17 Lingrui
- 4.17.1 Lingrui Company Information
- 4.17.2 Lingrui Business Overview
- 4.17.3 Lingrui Dermatology OTC Medications Sales, Revenue and Gross Margin (2021-2026)
- 4.17.4 Lingrui Dermatology OTC Medications Product Portfolio
- 4.17.5 Lingrui Recent Developments
5 Global Dermatology OTC Medications Market Scenario by Region
- 5.1 Global Dermatology OTC Medications Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Dermatology OTC Medications Sales by Region: 2021-2032
- 5.2.1 Global Dermatology OTC Medications Sales by Region: 2021-2026
- 5.2.2 Global Dermatology OTC Medications Sales by Region: 2027-2032
- 5.3 Global Dermatology OTC Medications Revenue by Region: 2021-2032
- 5.3.1 Global Dermatology OTC Medications Revenue by Region: 2021-2026
- 5.3.2 Global Dermatology OTC Medications Revenue by Region: 2027-2032
- 5.4 North America Dermatology OTC Medications Market Facts & Figures by Country
- 5.4.1 North America Dermatology OTC Medications Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Dermatology OTC Medications Sales by Country (2021-2032)
- 5.4.3 North America Dermatology OTC Medications Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Dermatology OTC Medications Market Facts & Figures by Country
- 5.5.1 Europe Dermatology OTC Medications Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Dermatology OTC Medications Sales by Country (2021-2032)
- 5.5.3 Europe Dermatology OTC Medications Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Dermatology OTC Medications Market Facts & Figures by Country
- 5.6.1 Asia Pacific Dermatology OTC Medications Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Dermatology OTC Medications Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Dermatology OTC Medications Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Dermatology OTC Medications Market Facts & Figures by Country
- 5.7.1 South America Dermatology OTC Medications Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Dermatology OTC Medications Sales by Country (2021-2032)
- 5.7.3 South America Dermatology OTC Medications Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Dermatology OTC Medications Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Dermatology OTC Medications Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Dermatology OTC Medications Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Dermatology OTC Medications Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Dermatology OTC Medications Sales by Type (2021-2032)
- 6.1.1 Global Dermatology OTC Medications Sales by Type (2021-2032) & (M Units)
- 6.1.2 Global Dermatology OTC Medications Sales Market Share by Type (2021-2032)
- 6.2 Global Dermatology OTC Medications Revenue by Type (2021-2032)
- 6.2.1 Global Dermatology OTC Medications Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Dermatology OTC Medications Revenue Market Share by Type (2021-2032)
- 6.3 Global Dermatology OTC Medications Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Dermatology OTC Medications Sales by Application (2021-2032)
- 7.1.1 Global Dermatology OTC Medications Sales by Application (2021-2032) & (M Units)
- 7.1.2 Global Dermatology OTC Medications Sales Market Share by Application (2021-2032)
- 7.2 Global Dermatology OTC Medications Revenue by Application (2021-2032)
- 7.2.1 Global Dermatology OTC Medications Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Dermatology OTC Medications Revenue Market Share by Application (2021-2032)
- 7.3 Global Dermatology OTC Medications Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Dermatology OTC Medications Value Chain Analysis
- 8.1.1 Dermatology OTC Medications Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Dermatology OTC Medications Production Mode & Process
- 8.2 Dermatology OTC Medications Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Dermatology OTC Medications Distributors
- 8.2.3 Dermatology OTC Medications Customers
9 Global Dermatology OTC Medications Analyzing Market Dynamics
- 9.1 Dermatology OTC Medications Industry Trends
- 9.2 Dermatology OTC Medications Industry Drivers
- 9.3 Dermatology OTC Medications Industry Opportunities and Challenges
- 9.4 Dermatology OTC Medications Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst